NCT03619681View on ClinicalTrials.gov

Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 17, 2018

Primary Completion Date

June 30, 2022

Study Completion Date

August 26, 2022

Conditions
Breast CancerGastric Cancer
Interventions
DRUG

KN026

Patient will be intravenously administrated with one dose of KN026. dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.

Trial Locations (1)

200000

Fudan University Shanghai Cancer Hospital, Shanghai

All Listed Sponsors
lead

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

INDUSTRY

NCT03619681 - Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer | Biotech Hunter | Biotech Hunter